Biotechnology News and Research RSS Feed - Biotechnology News and Research

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Siemens and BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, have entered into a strategic collaboration. [More]
Pan Am Cancer Treatment Center announces publication of immuno-oncology text book

Pan Am Cancer Treatment Center announces publication of immuno-oncology text book

The Pan Am Cancer Treatment Center is pleased to announce the publication of a specialized textbook titled "Immuno-Oncology, from Bench to Bedside" which provides scientific rationale for the use of immunotherapy in the treatment of cancer. [More]
Innovative formula prevents risks, painful treatments in people with secondary blindness

Innovative formula prevents risks, painful treatments in people with secondary blindness

The Mexican company "Medical and Surgical Center for Retina" created a way to transport drugs, in order to avoid risks and painful treatments in people with secondary blindness due to chronic degenerative blindness such as diabetic retinopathy and degeneration of the eye. [More]
Researchers identify fast and accurate approach to diagnose respiratory tract infection

Researchers identify fast and accurate approach to diagnose respiratory tract infection

Researchers from the University of Manchester are part of a team that has identified an important new approach to diagnose infections in critically ill patients rapidly and accurately. [More]
TxCell’s pilot manufacturing facility activities put on temporary partial hold

TxCell’s pilot manufacturing facility activities put on temporary partial hold

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that it has temporarily put its pilot manufacturing facility activities at Besançon, France on partial hold. [More]

MedNet Solutions' cloud-based eClinical technology platform wins Silver 2015 Stevie Award

MedNet Solutions, an innovative SaaS-based eClinical technology company that supports the entire spectrum of clinical research, is pleased to announce that iMedNet, the company's intuitive, flexible and affordable cloud-based eClinical technology platform, has been awarded a Silver 2015 Stevie Award by the American Business Awards in the Health Products & Services Website category. [More]
Israeli researchers establish novel optogenetic method for cardiac pacing and resynchronization

Israeli researchers establish novel optogenetic method for cardiac pacing and resynchronization

Israeli researchers have successfully established a new approach for pacing the heart and synchronizing its mechanical activity without the use of a conventional electrical pacemaker. This novel biologic strategy employs light-sensitive genes that can be injected into the heart and then activated by flashes of blue light. [More]
3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology. 3SBio previously acquired the China rights from Apexigen in 2006. [More]

Wockhardt obtains final approval from FDA for marketing 5mg/ 5ml of Oxycodone HCl liquid

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 5mg/ 5ml of Oxycodone HCl liquid which is used in treatment of moderate to severe acute and chronic pain. Wockhardt is launching the product soon and will be amongst the few generic versions of this product in the market. [More]
VG Life Sciences receives U.S. patent for combination cancer therapy

VG Life Sciences receives U.S. patent for combination cancer therapy

VG Life Sciences, Inc., a biotechnology company developing therapies for cancer, autoimmune and infectious diseases, announced that the U.S. Patent and Trademark Office will issue Patent No. 9073985 covering VGLS' combination therapy for treating drug-resistant cancer by combining an autophagy inhibitor with a chemotherapy drug. [More]
Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec Biopharma is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with UK-based stem cell therapeutics company, ReNeuron. [More]
MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

MedDay, a biotechnology company focused on the treatment of nervous system disorders, reports additional positive data from its pivotal Phase III clinical trial, MS-SPI, with MD1003, a highly-concentrated pharmaceutical grade biotin, in patients with Progressive Multiple Sclerosis. [More]
Florida Institute finalizes funding agreement with TransGenex Nanobiotech

Florida Institute finalizes funding agreement with TransGenex Nanobiotech

The Florida Institute for the Commercialization of Public Research announced today that it has finalized a funding agreement with TransGenex Nanobiotech, Inc., a company that is developing nano-scale technologies for novel, cost-effective diagnostic and therapeutic agents against cancers and other inflammatory diseases. [More]
Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone. [More]
PAREXEL expands Perceptive MyTrials Data-Driven Monitoring solution

PAREXEL expands Perceptive MyTrials Data-Driven Monitoring solution

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today launched next generation risk-based monitoring capabilities, expanding its Perceptive MyTrials Data-Driven Monitoring (DDM) solution. [More]
Hitachi High-Technologies, QIAGEN form new strategic partnership to advance molecular testing

Hitachi High-Technologies, QIAGEN form new strategic partnership to advance molecular testing

Hitachi High-Technologies Corporation and QIAGEN N.V. have entered into a long-term strategic collaboration involving initiatives to deliver important advances in molecular testing. [More]
Findings could lead to treatments for chronic pain caused by nerve damage

Findings could lead to treatments for chronic pain caused by nerve damage

Non-narcotic treatments for chronic pain that work well in people, not just mice, are sorely needed. Drawing from human pain genetics, an international team led by Boston Children's Hospital demonstrates a way to break the cycle of pain hypersensitivity without the development of addiction, tolerance or side effects. [More]
GMP grade cell cryopreservation media

GMP grade cell cryopreservation media

AMSBIO has announced the launch of GMP grade STEM-CELLBANKER® manufactured in strict compliance with Japanese, EU, US, and PICS good manufacturing practice guidelines. [More]
Accurexa seeks FDA clearance to market BranchPoint device

Accurexa seeks FDA clearance to market BranchPoint device

Accurexa Inc., a biotechnology company focused on developing and commercializing novel neurological therapies, announced on Monday that it has filed a submission with the U.S. FDA for 510(k) clearance to market its BranchPoint device. [More]
Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion. [More]
Advertisement
Advertisement